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Abstract
Eosinophils are leukocytes that are released into the peripheral blood in a phenotypically
mature state and are capable of being recruited into tissues in response to appropriate sti-
muli. Eosinophils, traditionally considered cytotoxic effector cells, are leukocytes recruited
into the airways of asthma patients where they are believed to contribute to the develop-
ment of many features of the disease. This perception, however, has been challenged by
recent findings suggesting that eosinophils have also immunomodulatory functions and
may be involved in tissue homeostasis and wound healing. Here we describe a transcrip-
tome-based approach–in a limited number of patients and controls—to investigate the acti-
vation state of circulating human eosinophils isolated by flow cytometry. We provide an
overview of the global expression pattern in eosinophils in various relevant conditions, e.g.,
eosinophilic asthma, hypereosinophilic dermatological diseases, parasitosis and pulmonary
aspergillosis. Compared to healthy subjects, circulating eosinophils isolated from asthma
patients differed in their gene expression profile which is marked by downregulation of tran-
scripts involved in antigen presentation, pathogen recognition and mucosal innate immu-
nity, whereas up-regulated genes were involved in response to non-specific stimulation,
wounding and maintenance of homeostasis. Eosinophils from other hypereosinophilic dis-
orders displayed a very similar transcriptional profile. Taken together, these observations
seem to indicate that eosinophils exhibit non-specific immunomodulatory functions impor-
tant for tissue repair and homeostasis and suggest new roles for these cells in asthma
immunobiology.
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Introduction
Eosinophils are bone marrow-derived leukocytes that are released into the peripheral blood in
a phenotypically mature state where they represent less than 5% of the leukocyte population.
They are capable of being recruited to tissues in response to appropriate stimuli. In healthy
individuals, most eosinophils are found in the gut, mammary glands, uterus, thymus, bone
marrow and adipose tissues [1] but their role in these tissues at baseline conditions, as well as
their close interactions with mast cells, is still under investigation.
Mature human eosinophils contain crystalloid secondary granules, which are primarily
composed of highly charged basic proteins including two eosinophil granule major basic pro-
teins (MBPs), eosinophil cationic protein (ECP), eosinophil derived neurotoxin (EDN) and
eosinophil peroxidase (EPO). MBP, EPO, and ECP are toxic to a variety of tissues, including
the bronchial epithelium [1]. Eosinophils also express a broad range of cytokines; e.g. Th2
(such as IL-4, IL-5, IL-9, IL-13, and IL-25), Th1 (IL-12 and IFN-γ), acute pro-inflammatory
cytokines (TNF-α, IL-1β, IL-6 and IL-8), immune inhibitory cytokines (e.g, TGF-β and IL-10);
as well as receptors for many of these cytokines [1].
Eosinophils have been typically considered as end-stage destructive cells involved in host
protection against parasites [2]. They are also recruited into the airways of asthma patients and
the release of their granule proteins has been suggested to contribute to the development of
many features of asthma, including airways hyperresponsiveness and mucus hypersecretion
[3]. However, the development of different strategies over the last years targeting eosinophils
and their effector functions in patients with asthma has been disappointing and only reducing
exacerbations in a selected asthma population [4, 5]. Moreover data from genetically engi-
neered strains of mice affecting eosinophil effector functions or eosinophils themselves have
shown that eosinophils might be dispensable in allergic airway inflammation [6, 7].
The accumulation and increase in eosinophils are by no means unique to helminth infec-
tions and asthma, since blood and tissue eosinophilia is also encountered in numerous other
disorders, such as atopic dermatitis, Churg-Strauss syndrome, various infections, adverse drug
reactions, gastrointestinal disorders or certain malignancies [8]. Yet, their very role in such
hypereosinophilic diseases remains, surprisingly, unclear.
Recent findings in mouse models support a broader role for eosinophils and suggest that
they may be important in the regulation of the broader immune response. At baseline condi-
tions, recent work has indeed shown that eosinophils can contribute to homeostatic processes,
for example plasma cell maintenance in the bone marrow as well as metabolic homeostasis [9].
Other data indicate that these cells might also function as reparative cells during inflammatory
responses to heal injured tissues and to promote homeostasis [10, 11].
The aim of our work was to compare the transcriptional profile of circulating eosinophils
from asthma patients vs those from healthy controls and other hypereosinophilic diseases. Our
undermining working hypothesis was to uncover a disease-specific expression profile of eosin-
ophils in asthma versus healthy controls and/or other hypereosinophilic syndromes. Whole
genome expression analyses remain a fairly unbiased approach in comparing global gene activ-
ity between different states of a cell, tissue, organ, organism. In case of eosinophils however,
this approach has been hampered by the extreme difficulty to harvest these cells in sufficient
amounts and in a “healthy” state in order to obtain high grade RNA [12]. Having overcome
these technical hindrances, we managed to set-up a robust process for a transcriptome-based
analysis of eosinophils. Using circulating cells isolated from a limited number of healthy
donors and patients with eosinophilic asthma or other hypereosinophilic diseases, we report
here the transcriptional pattern of these cells. Our data suggest a common modulation of gene
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expression in disease upon cell activation and provide additional insights supporting a broad
role of eosinophils in tissue repair and homeostasis.
Material and Methods
Characteristics of subjects
Main characteristics of subjects are summarized in Table 1. Patients with asthma (n = 7) ran-
ged in age from 27 to 68, had persistent, moderate-to-severe disease and elevated blood eosino-
phil count (> 500 x 109/L). Five of them had also documented nasal polyposis. All asthmatics
patients were on high doses of inhaled corticosteroids, none of the subjects with asthma was
taking oral corticosteroids at the time of blood withdrawal. Subjects with peripheral hypereosi-
nophilia defined as in [13] related to other diseases were also recruited, including subjects with
dermatologic disease (n = 3, i.e prurigo, bullous pemphigoid and drug toxidermia), parasitosis
(n = 3, i.e giardiasis, ascaridiosis and scabies) and pulmonary aspergillosis (n = 5, with 2 of
them also suffering from asthma associated to bronchopulmonary aspergillosis.). Healthy non-
atopic control subjects (n = 10) had peripheral eosinophil counts below 500 x 109/L. Peripheral
ethylenediamine tetra-acetic acid (EDTA) anticoagulated blood was collected by venipuncture
(20 ml) as part of routine medical examination from subjects who gave their informed written
consent to this Institutional Review Board (Comité de Protection des Personnes–EST; STRAS-
BOURG) approved protocol.
Eosinophil isolation
First, granulocytes were isolated by density-gradient centrifugation over Histopaque 1077 and
Histopaque 1119 (Sigma Aldrich). Residual erythrocytes were lysed by Versalyse (Beckman
Coulter). The granulocyte suspension was stained with anti-CD45-PC7, CD24-PE and
CD16-PC5 (Beckman Coulter). Eosinophils were sorted from the granulocyte suspension by
FACSAria (BD Biosciences) based on FSC and SSC characteristics, CD45 and CD24 expression
and lack of CD16 expression. All steps were performed on ice. Eosinophil viability after FACS
sorting was assessed by trypan blue exclusion (>90%) and purity (>99%) was assessed by
FACS (data not shown) and cytospin (Fig 1B). Cells were stored in the lysis buffer (see below)
at -80°C until batch RNA extraction.
RNA extraction
Total RNA was extracted from sorted eosinophils using the RNeasy Micro Kit (Qiagen)
according to the manufacturer’s instructions. RNA concentration was assessed by a NanoDrop
spectrophotometer and RNA quality was measured using an Agilent Bioanalyzer. All RNA
samples included in the expression analysis had an RNA integrity number (RIN)> 8 (Fig 1C
and S1 Fig).
Table 1. Subject characteristics.
Control subjects Asthma Dermatological disease Parasitosis Pulmonary aspergillosis
n 10 7 3 3 5
Age (y), mean±SD 40.2±5.1 52.6±5.0 77.3±3.2 53±13.9 45.6±10.0
Sex (M/F) 3/7 5/2 2/1 3/0 2/3
Eosinophils (/mm3), mean±SD 137±27.37 1256±287.4 2753±587 1577±76.23 2866±1311
minmax 60340 5002880 16003520 14601720 11808050
doi:10.1371/journal.pone.0141740.t001
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Microarrays
Microarray analysis was performed according to Agilent protocol “Two-Color Microarray-
Based Gene Expression Analysis–Low Input Quick Amp Labeling” version 6.5, May 2010 (Cat
# G4140-90050). Test samples (asthma n = 4, healthy controls n = 3, dermatological disease
n = 3, pulmonary aspergillosis n = 4, parasitosis n = 3) were linearly amplified and labeled with
Cyanine 3, starting from 25 ng of total RNA. In parallel, the “Human Universal Reference
Total RNA” (Clonetech, Cat # 636538) was amplified and labeled with Cyanine 5. Each experi-
mental sample was then co-hybridized with the unique human universal reference on Agilent
“SurePrint G3 Human Gene Expression 8x60K Microarray” (Design ID 028004), for 17 hours,
Fig 1. Eosinophil isolation by FACS generates high quality RNA. (A) Flow cytometry gating strategy for the identification of eosinophils. Eosinophils were
identified among a granulocyte suspension (see Methods) as a CD16 fluorescence negative cell population (B) Purity of sorted eosinophils as assessed by
cytospin preparation was close to 100%. (C) Bioanalyzer RNA profile with RNA integrity number (RIN) of an eosinophil sample. All RNA samples included in
the expression analysis had a RIN > 8.
doi:10.1371/journal.pone.0141740.g001
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at 65°C under 10 rpm. Following washing, the slides were scanned using an Agilent G2565CA
microarray Scanner System, at a 3μm resolution in a 20-bit scan mode, according to the “Agi-
lentG3_GX_2Color” protocol. Raw.tiff images were then extracted using Agilent “Feature
Extraction, version 10.10.1.1” following “GE2_1010_Sep10” protocol. Median raw expression
values were further normalized by quantile method [14]. Differentially expressed (DE) genes
were selected using the fold change (FC) based method proposed by Dembélé et al [15]. This
method proceeds as follows: using pair of samples from two biological conditions, FCs are
computed for all the genes. These FCs are sorted in increasing order and their ranks are associ-
ated to genes. This is repeated with all the pair of samples in the dataset. An average rank is
computed and used as statistic leading to p-values for genes. Finally a threshold (0.01) is used
to select significant genes. Importantly, there is no multiple comparison issue(s) with this
method.
Gene ontology analyses
Functional enrichment was assessed using the DAVID database http://david.abcc.ncifcrf.gov/.
Real-time quantitative Reverse Transcription PCR (RT-qPCR)
Total RNA was reverse transcribed using the iScript cDNA Synthesis Kit according to the man-
ufacturer’s instructions (BioRad). Quantitative PCR was performed in a total volume of 20 μl
using SsoAdvancedTM SYBR Green Supermix kit (BioRad) and gene-specific primers: IL-8 3’
AGCACTCCTTGGCAAAACTG, IL-8 5’ CGGAAGGAACCATCTCACTG; AQP9 3’
TGCAACTGCCATTGAAAATC, AQP9 5’ AGTTCTTGGGCACGTTCATC; IL-2RA 3’
TAGGCCATGGCTTTGAATGT, IL-2RA 5’ ATACCTGCTGATGTGGGGAC; LIPA 3’
GCAAGGTTTGTGACCCAGTT, LIPA 5’ TGCCTTAACCGAATTCCTCA; IL-10RA 3’
GGTTCACACTGCCAACTGTC, IL-10RA 5’ ACCTTACCGCAGTGACCTTG; PMP22 3’
TTGGCAGAAGAACAGGAACA, PMP22 5’ CCTCAGGAAATGTCCACCAC; CD83 3’
GGGGTGTCTCCATCCTCTCT, CD83 5’ TGCTCCGAAGATGTGGACTT; CCL3 3’
TGGCTGCTCGTCTCAAAGTA, CCL3 5’ TGCAACCAGTTCTCTGCATC. After an initial
denaturation step at 96° C for 10 min, the cycling conditions were 95° C for 10 s/60° C for 30 s,
using a Rotor-Gene™ 6000 real-time PCR machine (Corbett Life Science). Amplification prod-
ucts were detected as an increased fluorescent signal of SYBR1Green during the amplification
cycles. Results were obtained using Rotor-Gene 6000 Series Software and evaluated using Excel
(Microsoft). Melting-curve analysis was performed to assess the specificity of PCR products.
Results were normalized to β-actin levels. The RT-qPCR results are presented as means and
standard error of the mean (SEM). Differences in the expression of mRNA were determined by
using a two-tailed non parametric Mann-Whitney test with the GraphPad Prism 6 software. P
values<0.05 were considered as significant.
Results
Isolation of eosinophils by fluorescence activated cell sorting (FACS)
yields high quality RNA
Eosinophils were efficiently isolated from human peripheral blood by FACS and identified as a
CD16 fluorescence negative cell population in an enriched granulocyte suspension (see Meth-
ods and Fig 1A). Eosinophils were kept at 4°C during the whole isolation process to block cell
activation. The purity of the sorted eosinophil population was close to 100%, as assessed by
FACS and cytoslides (Fig 1B). Using this isolation procedure, high quality RNA was obtained
from hypereosinophilic subjects and from healthy controls with RNA Integrity Numbers
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(RIN)> 8. A total amount of around 50 ng of total RNA was obtained from each sample (Fig
1C and S1 Fig).
Expression profiles of circulating eosinophils differ between asthmatic
and healthy subjects
For patient characteristics see Materials and Methods. Complete gene expression profiles from
peripheral eosinophils were generated from asthmatic patients (n = 4) and non-atopic healthy
controls (n = 3) upon RNA hybridization to Agilent microarrays measuring the expression lev-
els of 27,958 Entrez Genes. Supervised hierarchical clustering analysis of the top over- and
under- expressed genes (Fig 2) and unsupervised hierarchical clustering (S2 and S3 Figs)
enabled us to discriminate asthmatic subjects from healthy controls. Statistical analysis [15]
identified a total of 47 genes displaying a 2-fold or greater (21 up-regulated, 26 down-regu-
lated) variation in eosinophils of asthmatic subjects when compared to healthy controls.
Table 2 shows the list of genes with significant mRNA expression fold changes in circulating
eosinophils of patients with asthma compared to healthy controls. Remarkably, several of the
transcripts exhibiting significant up- or down-modulation—i.e, IL-2RA, IL-3RA, GSTT1,
EGR1, EGR2, PMP22, IL-8—have been reported in previous studies to be regulated in blood
eosinophils in response to in vitro exposure to IL-5 or granulocyte macrophage-colony-stimu-
lating factor (GM-CSF), cytokines considered as the most active triggers of eosinophil activa-
tion [16] [17] [18]. An overview of the function of these 47 genes suggests that most of them
exhibit immune-related functions (Table 2). Indeed, the most strongly up-regulated (20.33
fold) gene was DEFB105B, an effector component of the innate immune system supposed to
have broad antimicrobial activity [19]. The most strongly down-regulated genes also encode
immune-related genes; HLA class II, -11.38 fold and the TLR1, -5.47 fold. In addition, Prosta-
glandin-endoperoxide synthase 2 (PTGS2), a key enzyme for pro-inflammatory prostaglandin
production and IL-8, a major pro-inflammatory cytokine, were also down-regulated (-2.95 and
-2.32 fold respectively). CHRM4 a receptor for acetylcholine was up regulated (2.05 fold), thus
confirming recent findings suggesting that acetylcholine can regulate functions in the respira-
tory tract, including inflammation and remodeling during inflammatory lung diseases [20].
Other genes encode cell surface proteins (i.e., IL-2 receptor alpha subunit (RA), IL-3RA, IL-
10RA), intracellular enzymes related to neutralization of oxidative stress (GSTT1) [21], tran-
scription factors (EGR1, EGR2) and proteins of unknown function (PMP22).
To get a broader view of these differentially expressed genes, gene ontology analysis was per-
formed using the DAVID database (Database for Annotation, Visualization and Integrated
Discovery) [22]. The statistically significant (p<0.01) functional categories (filtered to exhibit
at least 10% concordance), which were enriched, are predominantly related to response to sti-
muli (i.e., external, organic, biotic, chemical), homeostatic processes, response to wounding
and inflammatory responses (Table 3). Incidentally, this analysis also reveals a linkage between
this set of genes and asthma (p = 0.006) among few other diseases in this list (Table 3).
The above described microarray observations were validated by quantitative RT-PCR (RT-
qPCR) for 8 of the 47 differentially expressed genes. Results were obtained from remaining
RNA samples (n = 2) used in the microarray analysis and from newly obtained eosinophil
RNA samples (Fig 3). Despite differences that did not reach statistical significance in the case
of CD83, CCL3 and LIPA, gene expression modulation in eosinophils from asthmatic patients
is statistically (p = 0.0279, Spearman r = 0.7857) similar to our observation using microarrays,
as evidenced by a correlation analysis between the two sets of data (fold changes obtained with
Agilent microarrays vs. fold change calculated by RT-qPCR, data not shown).
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Fig 2. Circulating eosinophils in asthma differ in their gene expression profile when compared to
healthy subjects.Heat map of hierarchical clustering of the top expressed genes of circulating eosinophils
from subjects with asthma (n = 4) vs healthy controls (n = 3). The horizontal dendrogram represents the
relationship between asthmatic and healthy subjects. The vertical dendrogram represents the relationship
between the expression levels of each gene across all the samples. Over-expressed genes are shown in red
and under-expressed genes are depicted in green.
doi:10.1371/journal.pone.0141740.g002
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Table 2. Genes significantly up- or down-regulated in circulating eosinophils of patients with asthma compared to healthy controls.
Accession No. § Gene Symbol Gene Name Fold change
NM_001040703 DEFB105B defensin, beta 105B 20.33
NM_000709 BCKDHA branched chain keto acid dehydrogenase E1, alpha polypeptide 10.48
NM_002201 ISG20 interferon stimulated exonuclease gene 4.69
NM_015515 KRT23 keratin 23 (histone deacetylase inducible) 4.68
NM_019086 VSIG10 V-set and immunoglobulin domain containing 10 3.14
NM_032607 CREB3L3 cAMP responsive element binding protein 3-like 3 3.04
NM_000417 IL2RA# interleukin 2 receptor, alpha 2.92
NM_001558 IL10RA# interleukin 10 receptor, alpha 2.62
NM_002183 IL3RA interleukin 3 receptor, alpha (low afﬁnity) 2.53
ENST00000367534 ENST00000367534 Actin-related protein 2/3 complex subunit 5 (Arp2/3 complex 16 kDa subunit)(p16-ARC) 2.34
NM_000304 PMP22# peripheral myelin protein 22 2.28
NM_000853 GSTT1 glutathione S-transferase theta 1 2.22
NM_014020 TMEM176B transmembrane protein 176B 2.21
NM_005125 CCS copper chaperone for superoxide dismutase 2.18
NM_002966 S100A10 S100 calcium binding protein A10 2.17
NM_152331 ACOT4 acyl-CoA thioesterase 4 2.16
NM_000235 LIPA# lipase A, lysosomal acid, cholesterol esterase 2.16
NM_020879 CCDC146 coiled-coil domain containing 146 2.14
ENST00000449914 ENST00000449914 Unknown 2.10
NM_003806 HRK harakiri, BCL2 interacting protein (contains only BH3 domain) 2.09
NM_000741 CHRM4 cholinergic receptor, muscarinic 4 2.05
ENST00000399670 ENST00000399670 HLA class II histocompatibility antigen, DQ(1) beta chain Precursor (DC-3 beta chain) -11.38
NM_003263 TLR1 toll-like receptor 1 -5.47
NM_002123 HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 -4.58
NM_006167 NKX3-1 NK3 homeobox 1 -4.26
NR_003937 HLA-DQB2 major histocompatibility complex, class II, DQ beta 2 -3.49
NM_002982 CCL2 chemokine (C-C motif) ligand 2 -3.34
NM_005217 DEFA3 defensin, alpha 3, neutrophil-speciﬁc -3.32
NM_032882 PNMA6A paraneoplastic antigen like 6A -3.30
NM_000963 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) -2.95
NM_052926 PNMA5 paraneoplastic antigen like 5 -2.88
NM_020873 LRRN1 leucine rich repeat neuronal 1 -2.42
NM_021983 HLA-DRB4 major histocompatibility complex, class II, DR beta 4 -2.39
NM_020980 AQP9# aquaporin 9 -2.35
NM_000399 EGR2 early growth response 2 -2.35
NM_002983 CCL3# chemokine (C-C motif) ligand 3 -2.34
NM_000584 IL8# interleukin 8 -2.32
NM_001964 EGR1 early growth response 1 -2.32
NM_133271 FCAR Fc fragment of IgA, receptor for transcript variant 3 -2.31
NM_001925 DEFA4 defensin, alpha 4, corticostatin -2.31
NM_001772 CD33 CD33 molecule, transcript variant 1 -2.29
ENST00000366784 ENST00000366784 Inositol-trisphosphate 3-kinase B (EC 2.7.1.127) (IP3 3-kinase B)(IP3K-B)(IP3K B) -2.28
NM_001523 HAS1 hyaluronan synthase 1 -2.21
NM_138813 ATP8B3 ATPase, class I, type 8B, member 3 -2.20
NM_173198 NR4A3 nuclear receptor subfamily 4, group A, member 3, transcript variant 2 -2.12
NM_004665 VNN2 vanin 2, transcript variant 1 -2.09
(Continued)
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Hypereosinophilic disorders display a similar transcriptional profile to
asthma
Next, we checked whether these differentially expressed genes were specific to asthma. To this
end, we first isolated peripheral blood eosinophils from patients with other hypereosinophilic
disorders, including subjects with peripheral eosinophilia related to dermatological diseases,
Table 2. (Continued)
Accession No. § Gene Symbol Gene Name Fold change
NM_004233 CD83# CD83 molecule -2.04
§: GenBank accession numbers
#: genes chosen for validation by RT-qPCR.
doi:10.1371/journal.pone.0141740.t002
Table 3. Gene ontology categories with an enrichment score p<0.01 and > 10% of gene concordance
identified using the DAVID database.
Gene ontology category p Concordance (%)
glycosylation site:N-linked (GlcNAc. . .) 0.003 38,3
glycoprotein 0.004 38,3
topological domain:Cytoplasmic 0.004 34,
topological domain:Extracellular 0.001 31,9
molecular transducer activity 0.003 25,5
signal transducer activity 0.003 25,5
plasma membrane part 0.009 25,5
response to chemical stimulus 0.0004 23,4
response to external stimulus 0.0001 21,2
receptor activity 0.009 21,2
response to organic substance 0.0001 19,1
response to biotic stimulus 0.0002 14,8
behavior 0.0006 14,8
Immunoglobulin-like fold 0.001 14,8
multi-organism process 0.004 14,8
homeostatic process 0.007 14,8
regulation of cell proliferation 0.008 14,8
response to other organism 0.0005 12,7
inﬂammatory response 0.0008 12,7
negative regulation of cell proliferation 0.001 12,7
Cytokine-cytokine receptor interaction 0.002 12,7
multiple sclerosis 0.002 12,7
cell motion 0.004 12,7
Immunoglobulin-like 0.005 12,7
asthma 0.006 12,7
response to wounding 0.007 12,7
sarcoidosis 0.0001 10,6
response to bacterium 0.001 10,6
stomach cancer 0.002 10,6
anatomical structure formation involved in morphogenesis 0.008 10,6
response to hormone stimulus 0.010 10,6
doi:10.1371/journal.pone.0141740.t003
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parasitosis and pulmonary aspergillosis (see Table 1 for the detailed characteristics of patients)
and realized similar microarray-based analysis of their transcriptome. As in case of asthmatic
eosinophils versus those of healthy controls, the transcriptomic profile in eosinophils isolated
from other hypereosinophilic conditions was also distinct from that of healthy subjects as
revealed by volcano plots (Fig 4); highlighting only genes with a statistically significant
(p<0.01) fold change (red dots). In addition, this representation also indicates that many genes
exhibit large, potentially pathophysiologically-relevant changes in their transcriptional profile.
But the p-value for these modifications in expression does not reach statistical significance, and
the corresponding genes are therefore excluded from the following analyses. These variations
likely reflect, at the molecular level, the inherent heterogeneity of our samples which is pheno-
typically evidenced by the clinical variations described in Table 1.
To obtain an overview of the genes differentially expressed in the different diseases, we first
selected those showing a statistically significant (p<0.01), higher or lower, expression level
with a minimum fold change (FC)>+/- 2 as compared to healthy subjects (S1 Table). The
comparison of these lists shows that only 23 to 37% (13/47 in asthma; 23/100 is aspergillosis;
61/163 in dermatological diseases and 30/87 in parasitosis) of genes were specifically modu-
lated in each of the four conditions (S4 Fig; S2 Table). Most of the transcriptional changes that
occur in patients’ eosinophils are unexpectedly common: 10 genes are common to the 4 dis-
eases, and 40 are found in 3 out of 4 of them, indicating a cross-disease transcriptional signa-
ture. To confirm and quantify this observation, we performed a correlation analysis of the FC
for each gene showing significant (p<0.01) differential expression in at least 1 condition (listed
in S2 Table). For each combination of disease tested, correlation (using a Spearman non-
parametric assay) appeared to be highly (p<0.0001) significant, which confirms the important
similarities between the transcriptional profiles determined for each condition.
Finally, using the complete list of genes with significant (p<0.01) fold change in at least one
of the diseases, we estimated the distribution of the log fold changes (lfc) in each disease group.
As expected, two peaks appear in the univariate analysis, corresponding to the groups of up-
Fig 3. RT-qPCR of selected genes.Gene expression was determined by RT-qPCR in eosinophils isolated from subjects with asthma and healthy controls.
Results were normalized to β-actin and expressed as fold change compared with samples from healthy controls. Results are presented as means and SEM.
*p<0.05; **p<0.01 (2-tailed non parametric Mann-Whitney).
doi:10.1371/journal.pone.0141740.g003
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and down-regulated genes, respectively (Fig 5). The bivariate analysis indicates that the modu-
lation of gene expression is very similar between two diseases, as revealed by (i) the fact the
genes which are characterized by opposite transcriptional profiles in one condition out of four
(depicted in black) are in minority compared to those which are modulated in the same direc-
tion in the four diseases (in red); and (ii) the very homogenous shape of the estimated density
plots between each couple of diseases. This analysis confirmed highly identical changes with
more than 95% of the regulated genes being similar in all conditions. Analyzing some individ-
ual genes, we additionally observed that transcriptional changes of outliers (i.e. NR4A3 with a
lfc> 2 in the dermatological disease group and a lfc< -1 in parasitosis group) were not statisti-
cally significant.
Discussion
Eosinophils circulate in low numbers in the peripheral blood in healthy individuals and their
detailed analysis has been limited by the difficulty to obtain pure cells in large amounts. Con-
ventional methods for eosinophil purification use immunomagnetic cell separation and require
Fig 4. Differentially expressed genes in unrelated hypereosinophilic diseases. Volcano plot of genes
differentially expressed between subjects with peripheral hypereosinophilia (i.e. asthma, dermatological
disease, parasitosis and pulmonary aspergillosis) vs. healthy controls. Genes with a p-value <0.01 are
depicted in red.
doi:10.1371/journal.pone.0141740.g004
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a large (120 ml) blood volume [23]. Moreover, eosinophils contain proteins with potent ribo-
nuclease activities, making RNA isolation challenging. For the present study, we setup an effi-
cient FACS-based protocol for isolating intact human eosinophils from peripheral blood. Only
small (20 ml) volumes of whole blood were necessary for eosinophil purification and subse-
quent high quality RNA extraction, even from healthy subjects generally exhibiting low levels
of circulating eosinophils.
The subsequent transcriptomics analysis by microarray of a pure isolated eosinophil popu-
lation, which, to our knowledge has not been realized so far in such setting, compared healthy
controls to asthmatic patients with peripheral hypereosinophilia. Indeed, whilst other groups
have previously established transcriptome signatures between healthy controls and other
hypereosinophilic diseases (i.e. eosinophilic esophagitis) this has been done in tissue samples
Fig 5. Eosinophils from asthmatic subjects display a similar transcriptional profile as eosinophils from other hypereosinophilic conditions.
Scatterplots are based on fold changes of selected genes that are differentially expressed at least in one hypereosinophilic disease (p< 0.01). Diagonal:
estimation of the density of log fold changes (lfc) for each variable. Upper elements: estimation of the bivariate density of each couple of variables. In red:
genes with a lfc changed to the same direction in all the conditions. In black: genes with a lfc changed to the opposite direction in at least one couple of
variables. With a cut-off for the lfc of 0.15, more than 95% of the probe sets have identical changes. Ast, asthma; Asp, pulmonary aspergillosis; Der,
dermatological disease; Par, parasitosis.
doi:10.1371/journal.pone.0141740.g005
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obtained by biopsies which by nature contain other (non-eosinophil) cellular elements [24,
25].
We identified 47 genes significantly modulated by at least 2-fold in asthmatic subjects. This
relatively small number of differentially expressed transcripts might reflect a poor plasticity of
this leukocytes subset when compared for example to CD8+ T cells in which 1566 differentially
regulated genes have been identified in severe asthma [26]. Interestingly, we noted that some of
the differentially expressed genes identified in the course of this study were already shown to
be regulated in eosinophils, thereby further validating our microarray data. For instance,
expression of IL-2RA, IL-3RA, GSTT1, EGR1, EGR2, PMP22 and IL-8 have been previously
reported to be regulated in blood eosinophils in response to in vitro exposure to IL-5 or granu-
locyte macrophage-colony-stimulating factor (GM-CSF) [18] [27] [16], two important growth
and maturation factors for eosinophils which stimulate their effector functions [1].
A first potential limit to these findings is that purified eosinophils may not completely and
accurately reflect the in vivo situation because of cell activation that could result from the isola-
tion procedure. However, in our hands, the expression of the eosinophil activation markers
CD69 or L-selectin (CD62L) between patients and healthy subjects remains constant, as it is
the case for unfractionated blood eosinophils [28]. Second, eosinophils are tissue-dwelling cells
and depending on their location and the microenvironment, their activation status might differ
[1]. While we cannot presently object to this caveat, we wish to stress that our transcriptomic-
based approach identified numerous genes critical in eosinophils function and therefore, pro-
vides the foundations for further expression studies using RT-qPCR aiming at selectively dif-
ferentiating circulating from resident cells. We were also unable to show a significant
regulation of some of already described eosinophil adhesion molecules such as integrins which
expression might be increased in inflammatory conditions [1]. Finally, our relatively small
sample size might have impeded the detection of all significantly regulated genes between
health and disease.
Traditionally, eosinophils are considered in disease as activated cells exhibiting destructive
capabilities through the release of cytotoxic and pro-inflammatory mediators and are linked in
many mouse models of allergic respiratory inflammation and human asthma studies to the
underlying pulmonary pathology [3, 29]. However, conflicting data have emerged, as recent
murine studies using complex genetic asthma models failed to support a significant role for
eosinophils in inflammatory tissue damage [7] [30]. Moreover, improvement of symptoms in
asthma patients after therapies targeting eosinophils have not been linear and have encoun-
tered limited success, even if eosinophil numbers are dramatically reduced in the blood and air-
ways following these therapies [4] [31] [5, 32] [33] [34]. In line with these observations, our
data indicate that cytotoxic markers such as granule proteins or cysteinyl leukotrienes are not
differentially expressed in asthmatic eosinophils vs controls, at least in peripheral eosinophils.
Furthermore, prostaglandin-endoperoxide synthase 2, a key enzyme in the production of pro-
inflammatory prostaglandins [35], and IL-8, a major pro-inflammatory cytokine [36], were
also down-regulated, suggesting that increased cytotoxic or pro-inflammatory actions are not
the hallmarks of circulating eosinophils in asthma.
DEFB105B, an alarmin, belonging to the beta-defensin family, was strongly up regulated in
asthmatic eosinophils. Recently, various defensins have been found to mediate tissue repair
and homeostasis. Indeed, human DEFB3 over-expression through viral transduction promotes
skin wound healing in a pig model [37]. S100A10, also known as p11, is another alarmin gene
which exhibits up-regulation in asthmatic eosinophils in our study. S100A10 is a well-described
binding partner of annexin A2, which is thought to play an anti-inflammatory role [38, 39].
S100A10 can also inhibit phospholipase A2 activity in vitro [40], a key enzyme for pro-inflam-
matory leukotriene, prostaglandine and platelet activating factor biosynthesis. In addition, our
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data indicate that LIPA, also known as cholesterol ester hydrolase, was up-regulated in eosino-
phils from asthmatic patients. LIPA plays a central role in the modulation of neutral lipid
metabolites in all cells [41]. Knockout mice for this gene develop severe abnormal cell prolifera-
tion and alveolar remodeling in the lung [42], relating LIPA to pulmonary homeostasis and
remodeling. These examples nicely support the current notion claiming that eosinophils,
besides their well-established damaging capabilities, might also contribute to heal tissues
injured during inflammatory reactions.
The accumulation and increase of eosinophils are not unique to asthma and helminth infec-
tions. Eosinophil proliferation is a common feature of numerous other unrelated inflammatory
disorders, such as adverse drug reactions, atopic dermatitis, Churg-Strauss syndrome, some
malignancies or yet eosinophilic gastrointestinal disorders [1]. Our data didn’t support a dis-
ease-specific transcriptional signature in circulating eosinophils from different hypereosino-
philic conditions. Surprisingly, a large number of genes were shared between eosinophils from
asthmatic subjects and eosinophils from other hypereosinophilic diseases. This underlines
again the non-specific role of circulating eosinophils in asthma and other hypereosinophilic
diseases and identifies this cell as a major secondary recruited cell in an ongoing inflammatory
process.
In conclusion, this is the first report of genome-wide transcriptomic analysis of human
peripheral blood eosinophils isolated from individual patients and healthy controls by flow
cytometry. A disease-specific transcriptional signature could not been identified (one has, how-
ever, to bear in mind the small sample size) but our results clearly support new non disease spe-
cific roles for eosinophils in pathophysiology, as being major non-specific immunodulators
recruited to inflammatory sites and participating in tissue repair and maintenance of
homeostasis.
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